Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892787129> ?p ?o ?g. }
- W2892787129 endingPage "356" @default.
- W2892787129 startingPage "356" @default.
- W2892787129 abstract "Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic®) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpaturev—C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. Moreover, in glioma, several OVs have clearly demonstrated both safety and a promising efficacy in the phase I clinical trials. Additionally, the safety of several OVs, such as pelareorep (Reolysin®), proved their safety and efficacy in combination with paclitaxel in breast cancer patients, but the outcomes of OVs as monotherapy against breast cancer have not provided a clear therapeutic strategy for OVs. The clinical trials of OVs against pancreatic cancer have not yet demonstrated efficacy as either monotherapy or as part of combination therapy. However, there are several oncolytic viruses that have successfully proved their efficacy in different preclinical models. In this review, we mainly focused on the oncolytic viruses that transitioned into clinical trials against melanoma, glioma, pancreatic, and breast cancers. Hence, we described the current status and future prospects of OVs clinical trials against melanoma, glioma, pancreatic, and breast cancers." @default.
- W2892787129 created "2018-10-05" @default.
- W2892787129 creator A5003390713 @default.
- W2892787129 creator A5012051690 @default.
- W2892787129 creator A5014954218 @default.
- W2892787129 creator A5018146056 @default.
- W2892787129 creator A5032990646 @default.
- W2892787129 creator A5034042835 @default.
- W2892787129 creator A5034886325 @default.
- W2892787129 creator A5053467838 @default.
- W2892787129 creator A5058830508 @default.
- W2892787129 creator A5074008074 @default.
- W2892787129 creator A5078280466 @default.
- W2892787129 creator A5080220066 @default.
- W2892787129 creator A5081272654 @default.
- W2892787129 creator A5088447173 @default.
- W2892787129 creator A5089229760 @default.
- W2892787129 date "2018-09-26" @default.
- W2892787129 modified "2023-10-16" @default.
- W2892787129 title "The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers" @default.
- W2892787129 cites W131280268 @default.
- W2892787129 cites W1527334553 @default.
- W2892787129 cites W1583371546 @default.
- W2892787129 cites W1675112595 @default.
- W2892787129 cites W1929814745 @default.
- W2892787129 cites W1940241680 @default.
- W2892787129 cites W1966732847 @default.
- W2892787129 cites W1970212185 @default.
- W2892787129 cites W1970598746 @default.
- W2892787129 cites W1971532562 @default.
- W2892787129 cites W1976177182 @default.
- W2892787129 cites W1977890900 @default.
- W2892787129 cites W1978558644 @default.
- W2892787129 cites W1981989535 @default.
- W2892787129 cites W1983766005 @default.
- W2892787129 cites W1985107444 @default.
- W2892787129 cites W1985641036 @default.
- W2892787129 cites W1987741335 @default.
- W2892787129 cites W1987904386 @default.
- W2892787129 cites W1989864656 @default.
- W2892787129 cites W1999009503 @default.
- W2892787129 cites W2000971565 @default.
- W2892787129 cites W2008393860 @default.
- W2892787129 cites W2011320782 @default.
- W2892787129 cites W2017139885 @default.
- W2892787129 cites W2017576006 @default.
- W2892787129 cites W2018535642 @default.
- W2892787129 cites W2020609902 @default.
- W2892787129 cites W2024327551 @default.
- W2892787129 cites W2026406742 @default.
- W2892787129 cites W2028182670 @default.
- W2892787129 cites W2028577286 @default.
- W2892787129 cites W2030612376 @default.
- W2892787129 cites W2031946360 @default.
- W2892787129 cites W2032084713 @default.
- W2892787129 cites W2036044314 @default.
- W2892787129 cites W2037171350 @default.
- W2892787129 cites W2038709470 @default.
- W2892787129 cites W2039161614 @default.
- W2892787129 cites W2039225116 @default.
- W2892787129 cites W2042351268 @default.
- W2892787129 cites W2049092411 @default.
- W2892787129 cites W2054210536 @default.
- W2892787129 cites W2057382033 @default.
- W2892787129 cites W2071260213 @default.
- W2892787129 cites W2072564990 @default.
- W2892787129 cites W2073134590 @default.
- W2892787129 cites W2074525970 @default.
- W2892787129 cites W2076674654 @default.
- W2892787129 cites W2082150850 @default.
- W2892787129 cites W2082904403 @default.
- W2892787129 cites W2086591619 @default.
- W2892787129 cites W2091913868 @default.
- W2892787129 cites W2094949672 @default.
- W2892787129 cites W2096574915 @default.
- W2892787129 cites W2097995306 @default.
- W2892787129 cites W2099648846 @default.
- W2892787129 cites W2110410873 @default.
- W2892787129 cites W2115862526 @default.
- W2892787129 cites W2118728917 @default.
- W2892787129 cites W2135002443 @default.
- W2892787129 cites W2137723371 @default.
- W2892787129 cites W2139248662 @default.
- W2892787129 cites W2144624167 @default.
- W2892787129 cites W2148586577 @default.
- W2892787129 cites W2151286180 @default.
- W2892787129 cites W2155304024 @default.
- W2892787129 cites W2163492712 @default.
- W2892787129 cites W2165038732 @default.
- W2892787129 cites W2165320653 @default.
- W2892787129 cites W2165652424 @default.
- W2892787129 cites W2183585286 @default.
- W2892787129 cites W2191394457 @default.
- W2892787129 cites W2235523093 @default.
- W2892787129 cites W2263008850 @default.
- W2892787129 cites W2332940131 @default.
- W2892787129 cites W2336525273 @default.
- W2892787129 cites W2399245969 @default.